Supplemental Material - Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline PASI from week 4-40

Name: Supplemental Material - Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline PASI from week 4-40
Creator: Richard Langley
Published: 2024-01-16T15:24:00.100Z
Keywords: Psoriasis

Langley, Richard; Sanyal, Chiranjeev; Situ, Aaron; Alulis, Sarah; Hassan, Fareen; Peterson, Steve; Teneralli, Rachel; Lee, Jennifer; Patel, B; Disher, Tim

doi:10.17632/tv5xr9s7xs.1

Supplemental Material - Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline PASI from week 4-40

Published: 16 January 2024| Version 1 | DOI: 10.17632/tv5xr9s7xs.1

Contributors:

Richard Langley, Chiranjeev Sanyal, Aaron Situ, Sarah Alulis, Fareen Hassan, Steve Peterson, Rachel Teneralli, Jennifer Lee, B Patel, Tim Disher

Description

This is supplemental material for the manuscript: Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline PASI from week 4-40

Supplemental Material - Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline PASI from week 4-40

Description

Files

Categories

Licence